- One of the most prominent weaknesses of the business is low financial leverage. Bio-Rad is currently operating at a debt equity ratio of 0.6:1. If this situation continues it may lead to serious repercussions for the company (Data monitor, 2010).
- Its global operations make it vulnerable to various economic and market risks in the countries in which it is operating (Bio-Rad Laboratories, 2011).
- Company has reported to have significant deficiencies in its internal control over financial reporting at 31st December 2010 (Bio-Rad Laboratories, 2011).
Opportunities in Bio-Rad
1. Since its incorporation in 1952, Bio-Rad is expanding its business horizontally by mergers, acquisitions and strategic alliances. These alliances help company obtain a larger customer base dispersed in various geographic location and take benefit of the knowledge and expertise of the acquired company to provide new and improved products and thus larger profits (Data monitor, 2010).
2, with the advent of profitable business trends in medical equipment industry, prospects of biotech industries to have sustainable growth in future are very sharp (Data monitor, 2010).